CDEK
← All drugs Report issue

interferon alpha-2a

Trade name: roferon-a

Recombinant proteinapprovedOrphan Drug FDA

Approved

Jun 4, 1986

Clinical trial activity

74 trials · 75 clinical orgs · 1 marketing orgs

Phase 1
16
Phase 2
46
Phase 3
9
Phase 4
10

Earliest trial started Sep 1, 1994 (NCT00483132)

Timeline

1980s

  1. Jun 4, 1986

    Earliest FDA Approval

  2. Dec 14, 1987

    Orphan Drug Designation

  3. Nov 21, 1988

    Roche — First NDA Organization

  4. Nov 21, 1988

    Roche — NDA Organization

1990s

  1. Jan 1, 1994

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 1995

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2010

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedJun 4, 1986

Chemistry & pharmacology

Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Also known as

  • alpha interferon
  • alpha-interferon
  • human leukocyte interferon
  • interferon alpha-2a
  • reiferon

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07288112Phase 1/Phase 2 (Phase 2)Jan 31, 2026Diakonos Oncology Corporation
NCT07307586Phase 3Sep 1, 2025Zhengzhou University
NCT06650852Phase 2Nov 30, 2024Brii Biosciences
NCT06491563Phase 2Aug 31, 2024Brii Biosciences, Vir Biotechnology, Inc.
NCT06092333Phase 2Jan 3, 2024National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT05756166Phase 1/Phase 2 (Phase 2)Dec 30, 2023National Cancer Institute (NCI), State University of New York, Buffalo
NCT05799612Phase 1Sep 30, 2023University of Texas at Houston
NCT05970289Phase 2Aug 22, 2023Brii Biosciences, Vir Biotechnology, Inc.
NCT05961098Phase 2Aug 21, 2023Suzhou Ribo Life Science Co. Ltd.
NCT05941845Phase 2Jul 24, 2023University of Nice Sophia Antipolis
NCT05771402Phase 4Jun 1, 2023Chongqing Medical University, Guizhou Medical University, Southwest Medical University
NCT05535764Phase 1Jan 30, 2023University of Utah
NCT05612581Phase 1/Phase 2 (Phase 2)Nov 9, 2022Vir Biotechnology, Inc.
NCT05244057Phase 2Aug 23, 2022Huazhong University of Science and Technology, Jiao Tong University, Shanghai HEP Pharmaceatical Co., Ltd.
NCT05107778Phase 2Dec 17, 2021Ascletis Pharmaceuticals Co., Ltd.
NCT05005507Phase 2Nov 3, 2021Janssen Pharmaceutica NV
NCT04980482Phase 2Oct 29, 2021Arbutus Biopharma Corporation
NCT04781647Phase 2Feb 18, 2021Assembly Biosciences
NCT04667104Phase 2Feb 1, 2021Janssen Pharmaceutica NV
NCT04439539Phase 2Sep 14, 2020Janssen Pharmaceutica NV
Showing 20 of 74 trials
Page 1 / 4

Organizations

Research & Development (75)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Sun Yat-Sen UniversityAcademic/Hospital7732015
Capital Medical UniversityAcademic/Hospital6532013
Vir Biotechnology, Inc.For profit4212020
Brii BiosciencesFor profit3312023
Cairo UniversityAcademic/Hospital3022009
Janssen Pharmaceutica NVFor profit3312020
Jiao Tong UniversityAcademic/Hospital3122014
University of Texas at HoustonAcademic/Hospital3321996
Ain Shams UniversityAcademic/Hospital2022009
Bristol-Myers SquibbFor profit2212015
Enyo PharmaFor profit2222017
Fortune RockFor profit2222013
Menoufia UniversityAcademic/Hospital2122009
MinaPharm PharmaceuticalsFor profit2212012
National Cancer Institute (NCI)Government2111995
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Government2212018
National Institute on Drug Abuse (NIDA)Government2022007
University of TuebingenAcademic/Hospital2212004
Alnylam PharmaceuticalsFor profit1012020
Arbutus Biopharma CorporationFor profit1112021
75 organizations
Page 1 / 4

Marketing (1)

OrganizationOrg typeRelationshipDate
RocheFor profitNDANov 21, 1988